The Food and Drug Administration (FDA) has approved Jazz Pharmaceutical's drug, Modeyso, which targets cancer cells directly to kill them. The drug can extend a patient's life span, mitigate symptoms and slowly eliminate the tumor. The most common form of DMG is a once-a-day pill, given to patients 1 year and older. Modeyso has been developing for years and is now being tested to potentially respond to other brain tumors. The disease, which spreads rapidly, is caused by rapid brain development and rapid mutations.